Sangamo announces updated data from STAAR study
Sangamo (SGMO) announced updated data from the Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned gene ...
Sangamo reports positive Fabry disease gene therapy results
RICHMOND, Calif. - Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company with a market capitalization of $263 million, has announced promising updated results from its Phase 1/2 STAAR ...
来自MSN3 小时
Top 10 most common cancers in Rwanda
In Rwanda, cancer remains a leading health challenge, with breast, cervical, and prostate cancers being among the most prevalent. According to Dr. Theoneste Maniragaba, the Director of the Cancer ...
expresshealthcare22 小时
GOQii partners with Acrannolife Genomics to launch GrafCare program
The long-term vision for GrafCare includes expanding into global markets, particularly in Southeast Asia and the Middle East, ...